Statins and Cognition in Parkinson's Disease

被引：13

作者：

Deck, Benjamin L. ^{[1
]}

Rick, Jacqueline ^{[1
]}

Xie, Sharon X. ^{[2
]}

Chen-Plotkin, Alice ^{[1
]}

Duda, John E. ^{[1
,5
]}

Morley, James F. ^{[1
,5
]}

Chahine, Lana M. ^{[1
]}

Dahodwala, Nabila ^{[1
]}

Trojanowski, John Q. ^{[3
]}

Weintraub, Daniel ^{[1
,4
,5
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Dept Biostat, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA

[4] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA

[5] Michael J Crescenz Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA

来源：

JOURNAL OF PARKINSONS DISEASE | 2017年 / 7卷 / 04期

关键词：

Apolipoprotein A-I; cognition; hydroxymethylglutaryl-CoA reductase inhibitors; longitudinal studies; Parkinson's disease; reactive oxygen species; PLASMA APOLIPOPROTEIN A1; REDUCTASE INHIBITORS; ALZHEIMERS-DISEASE; RISK; DEMENTIA; METAANALYSIS; CHOLESTEROL; SIMVASTATIN; COMMUNITY; TRIAL;

D O I：

10.3233/JPD-171113

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Background: The relationship between statins and cognition in Parkinson's disease (PD) is poorly understood. Objectives: Analyses were performed to determine associations between statin use and cross-sectional and longitudinal cognitive performance in PD. Methods: Neuropsychological tests, medication logs, and ratings of functional abilities were collected from 313 PD participants longitudinally. Results: At baseline, statin users (SU; N=129) were older, more likely male, and had shorter PD duration than non-statin users (NSU; N=184). In Cross-sectional analysis, SU performed better on global cognition, Trails B, semantic fluency, and phonemic fluency tasks. Rate of long-term global cognitive (Dementia Rating Scale-2 and MoCA) decline was significantly less in SU.

引用

页码：661 / 667

页数：7

共 50 条

[1] Cognition and Parkinson's disease
Garrett, MC
Fonseca, MR
Rosas, MJ
Simoes, F
Vieira, S
MOVEMENT DISORDERS, 2002, 17 : S128 - S128
[2] Statins associated with Parkinson's disease
Reactions Weekly, 2016, 1626 (1) : 11 - 11
[3] Cognition in Parkinson's disease
Basic, J
Katic, S
Vranic, A
Zarevski, P
Babic, T
Mahovic-Lakusic, D
CROATIAN MEDICAL JOURNAL, 2004, 45 (04) : 451 - 456
[4] Cognition in Parkinson's Disease
O'Callaghan, Claire
Lewis, Simon J. G.
NONMOTOR PARKINSON'S: THE HIDDEN FACE: THE MANY HIDDEN FACES, 2017, 133 : 557 - 583
[5] Association between statins and Parkinson's disease
Reactions Weekly, 2017, 1658 (1) : 10 - 10
[6] Linking Statins and Lipids in Parkinson's Disease
Ng, Adeline S. L.
Tan, Eng-King
MOVEMENT DISORDERS, 2017, 32 (06) : 807 - 809
[7] Kickboxing and Cognition in Parkinson's Disease
McLeod, Colin
Delambo, Amy
Delambo, Ali
Turner, Travis
Hinson, Vanessa
NEUROLOGY, 2019, 92 (15)
[8] COGNITION AND GAIT IN PARKINSON'S DISEASE
Fatima, A.
PARKINSONISM & RELATED DISORDERS, 2020, 79 : E25 - E25
[9] Cognition and language in Parkinson's disease
Kralova, M.
Izakova, L.
Hajduk, M.
Kosutzka, Z.
Kusnirova, A.
Markova, J.
Csefalvay, Z.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S331 - S332
[10] Assessment of cognition in Parkinson's disease
Marinus, J
Visser, M
Verwey, NA
Verhey, FRJ
Middelkoop, HAM
Stiggelbout, AM
van Hilten, JJ
NEUROLOGY, 2003, 61 (09) : 1222 - 1228

← 1 2 3 4 5 →